Skip to main content
PEPTARA LABS
Get Started
Peptara Labs AOD-9604 10mg vial
Growth hormone fragment

AOD-9604 Peptide for Sale

Published by · Updated · How we research and check our pages

Growth Hormone Fragment, Studied in Mice

AOD-9604 peptide from Peptara Labs (peptaralabs.io) is a 10mg research-grade vial for $74 USD, the AOD-9604 Black Friday price: 45% off the regular $135, and it ships as soon as stock arrives. Its batch certificate of analysis is pending, so no purity figure is claimed yet. It is sold for research use only.

Black Friday price, 45% off, ends November 30

$74 USDWas $135 USD

Black Friday price, 45% off, ends November 30

Flat $35 tracked shipping10mg per vial

Ships as soon as stock arrives

1vial

$74 USD

Was $135

$74.00 per vialWas $135.00Black Friday price

Add 2 more, unlock 50%

Vials of any product count together in your cart: 1 to 2 vials 45% off, 3 to 4 vials 50% off, 5 to 9 vials 55% off, 10 or more 60% off. No code is added on top.

Batch certificate pending
Peptara Labs AOD-9604 10mg vial

Shipping, delivery and certificate status

Shipping
Flat $35, tracked worldwide to supported markets
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Included
Vial · Batch certificate pending · Order support on WhatsApp

Buyer facts

What do you get when you buy AOD-9604 from Peptara Labs?

One sealed 10mg vial of lyophilized AOD-9604 powder. The order contains this vial only.

DetailAOD-9604Where to check it
CompoundAOD-9604, also written AOD9604Identity checks below
Vial10mg, sealed lyophilized powderVial listing
Price$74 USD, the AOD-9604 Black Friday price: 45% off the regular $135Order panel above
AvailabilityPre-order. Ships as soon as stock arrives. Delivery follows dispatch.Shipping note above
CertificateBatch certificate pendingCertificate status
UseLaboratory research onlyResearch-use label

Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

Research vial
Batch certificate pending
Delivery information with your order
Order support

Share or cite this page

Add as preferred on Google

Sources: PubChem, CID 71300630.

Before you buy

What should you check before you buy AOD-9604?

AOD-9604, AOD9604 and the seller label "fragment 176-191" often refer to this research peptide. The safety summary describes its structure as positions 177 to 191 of human growth hormone with an added tyrosine.

A certificate should identify the compound by mass spectrometry and report purity by HPLC. PubChem lists formula C78H123N23O23S2 and molecular weight 1815.1 g/mol. A name on a listing does not replace those checks. This batch certificate is pending and no measured purity is claimed.

The peptide purity guide explains the checks, and the certificates page shows current status.

Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; PubChem, CID 71300630.

The short answer

What is AOD-9604?

AOD-9604 is a 16 amino acid peptide built from the end of human growth hormone with an added tyrosine. Researchers designed it to keep the part tied to fat breakdown while leaving out other growth hormone signals.

That design is a research idea. Mouse and rat studies measured fat metabolism, and six human trials were later summarized for safety. This vial is research material and is not an approved weight-loss medicine.

Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Ng et al., 2000, Horm Res, PMID 11146367; Heffernan et al., 2001, Endocrinology, PMID 11713213; FDA safety-risk listing, content current April 22, 2026.

The science

How was AOD-9604 designed to work?

The idea separates lipolysis, the breakdown of stored fat, from lipogenesis, the building of new fat. In obese mice, researchers measured lower body weight and fat over 14 days and a return of beta-3 receptor RNA toward lean-animal levels. Mice without that receptor did not show the same weight change, although a short-term test still found higher energy use.

A rat study measured weight gain over 19 days. In obese Zucker rats, it was less than half that of controls, with no adverse change in insulin sensitivity. The six-trial human safety summary found no change in IGF-1. These findings describe the study models and do not predict a personal result.

Fat-metabolism hypothesis

A small growth hormone fragment was designed around fat-breakdown signaling.

Beta-3 receptor link

Mouse comparisons tested whether the beta-3 receptor was needed for the weight change.

IGF-1 remained unchanged

The human safety summary recorded no change in IGF-1 across six trials.

Sources: Heffernan et al., 2001, Endocrinology, PMID 11713213; Ng et al., 2000, Horm Res, PMID 11146367; Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w.

Applications

What has AOD-9604 been studied in?

Obesity models

Mouse and rat studies measured body fat, weight change and metabolic signals.

Insulin sensitivity

A rat study used clamp testing to examine glucose handling.

Human safety trials

A paper summarized six controlled trials with 893 participants.

Knee cartilage damage

A rabbit model examined cartilage tissue scores.

Sources: Heffernan et al., 2001, Endocrinology, PMID 11713213; Ng et al., 2000, Horm Res, PMID 11146367; Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Kwon and Park, 2015, Ann Clin Lab Sci, PMID 26275694.

Comparison

AOD-9604 vs tesamorelin and other growth hormone peptides

AOD-9604 is a hormone fragment. The other molecules below raise or imitate signals that lead to growth hormone release. Their study records answer different questions.

CompoundWhat it isEffect on IGF-1Study record
AOD-960416 amino acid growth hormone fragmentNo change in six trialsA six-trial human safety summary, plus animal metabolism studies
TesamorelinGHRH analogRose 81% in the cited trial412 people with HIV: visceral fat fell 15.2% versus a 5.0% rise with placebo
CJC-1295Long-acting GHRH analogSustained increase in healthy adultsControlled human study of growth hormone and IGF-1 signals
IpamorelinSelective growth hormone secretagogueNot established by the cited paperThe early paper identified its selective growth hormone signal
MK-677Ghrelin mimeticNot quantified on this pageA randomized trial found higher fasting glucose and lower insulin sensitivity

Separate pages cover tesamorelin, CJC-1295 and ipamorelin, and MK-677. The AOD-9604 comparison guide covers a separate medicine class.

Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Falutz et al., 2007, N Engl J Med, PMID 18057338; Teichman et al., 2006, J Clin Endocrinol Metab, PMID 16352683; Raun et al., 1998, Eur J Endocrinol, PMID 9849822; Nass et al., 2008, Ann Intern Med, PMID 18981485.

Evidence

What did the AOD-9604 studies report?

Mouse metabolism study

Model: Obese mice and mice without the beta-3 receptor.

Reported: Researchers measured weight, fat, receptor RNA and energy use.

Rat insulin-sensitivity study

Model: Obese Zucker rats.

Reported: Weight gain was lower than controls, with no adverse change in insulin sensitivity.

Six-trial safety review

Model: 893 human participants across six controlled trials.

Reported: The paper recorded safety findings and no change in IGF-1.

Rabbit cartilage study

Model: A rabbit model of knee cartilage damage.

Reported: Researchers assessed cartilage tissue scores.

The human trial ledger: six trials, 893 people

Trial codePhasePeopleLengthWhat it measured
METAOD001I15 healthy menSingle sessionsSafety
METAOD002IIa23 obese menSingle sessionsSafety
METAOD003IIa17 obese menSingle sessionsSafety
METAOD004IIa36 obese men7 daysSafety
METAOD005IIb300 obese adults12 weeks planned, 14-week periodEfficacy and safety
METAOD006IIb502 obese adults randomized24 weeksEfficacy and safety

The safety summary found no change in IGF-1, no adverse effect on glucose tolerance and no antibodies. It reported no withdrawals or serious adverse events tied to AOD-9604, with safety similar to placebo. The paper reports safety and does not supply the weight-change findings needed to judge efficacy.

The FDA lists AOD-9604 among substances nominated for compounding and then withdrawn. Its page notes immune-reaction risk, limited safety information and serious adverse events that may be linked to the compound, with the cause unclear. That regulatory warning sits alongside the earlier trial report; neither establishes that this research vial is safe for a person.

Sources: Heffernan et al., 2001, Endocrinology, PMID 11713213; Ng et al., 2000, Horm Res, PMID 11146367; Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Kwon and Park, 2015, Ann Clin Lab Sci, PMID 26275694; FDA safety-risk listing, content current April 22, 2026.

What is not known

What is still unknown about AOD-9604?

The references on this page do not establish a peer-reviewed half-life figure or long-term human safety. A number borrowed from another growth hormone fragment would not answer that gap.

ClinicalTrials.gov searches for AOD9604 and AOD-9604 returned zero registered studies on October 7, 2026. The safety paper describes six trials notified in Australia, so that registry search does not erase the trial record.

Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; ClinicalTrials.gov searches, October 7, 2026; FDA safety-risk listing, content current April 22, 2026.

Research timeline

How the AOD-9604 record was built

Research timeline

How the AOD-9604 record was built

2000: rat metabolism

Researchers measured weight gain and insulin sensitivity in obese Zucker rats.

2001: beta-3 receptor studies

Mouse studies compared animals with and without the beta-3 receptor to test its role in fat metabolism.

2013: six-trial safety summary

A paper summarized safety findings from six controlled trials involving 893 people.

2015: knee cartilage research

Researchers assessed tissue scores in a rabbit model of knee cartilage damage.

2026: FDA safety-risk listing

The FDA listed AOD-9604 among compounding nominations that were withdrawn and described safety concerns.

Your Kit

What's Included

AOD-9604 research vial

$74 USD Was $135 USD

Flat $35 tracked shipping · Ships as soon as stock arrives · Batch certificate pending · Order support on WhatsApp

Black Friday price, 45% off, ends November 30

Order AOD-9604

AOD-9604 10mg Vial

10mg per vial

Batch certificate

Batch certificate pending

Delivery

Ships as soon as stock arrives · After dispatch: 5 to 10 business days

Order support

Contact our team about your order or batch certificate.

Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

Research vial
Batch certificate pending
Delivery information with your order
Order support

Your Research Order

AOD-9604 research vial, batch certificate status, delivery and order support.

Batch certificate

Batch certificate pending

Delivery

Ships as soon as stock arrives · After dispatch: 5 to 10 business days

Order support

Contact our team about your order or batch certificate.

Order AOD-9604

Questions

Buying AOD-9604: FAQ

How much is AOD-9604 at Peptara Labs?

A 10mg research vial is $74 USD, the AOD-9604 Black Friday price: 45% off the regular $135. Ships as soon as stock arrives. Delivery follows dispatch. It is sold for research use only.

Where can I buy AOD-9604?

Peptara Labs lists AOD-9604 as a 10mg research vial on this page. Its batch certificate is pending, so no purity figure is claimed yet.

Is a batch certificate available for this AOD-9604 vial?

The batch certificate of analysis is pending. No purity figure, test date or batch number is claimed before a certificate is released.

AOD-9604 research FAQ

What is AOD-9604?

AOD-9604 is a 16 amino acid peptide built from the end of human growth hormone, positions 177 to 191, with an added tyrosine. It was made to keep the part tied to fat breakdown and leave out other hormone signals.

Is AOD-9604 the same as growth hormone?

No. AOD-9604 is a small fragment with an added tyrosine, rather than the whole hormone. The six trials summarized in 2013 found no change in IGF-1.

Does AOD-9604 raise IGF-1?

Six human trials summarized in 2013 found no change in IGF-1 levels. GHRH analogs such as tesamorelin have a different structure and raised IGF-1 in research.

What side effects did AOD-9604 trials record?

The 2013 summary of six controlled trials reported a safety profile similar to placebo, with no antibodies found. The FDA notes serious adverse events that may be linked to AOD-9604, though the cause is not clear.

Is AOD-9604 the same as tesamorelin?

No. Tesamorelin is a GHRH analog that raises growth hormone and IGF-1, and it has a large controlled trial in people with HIV. AOD-9604 is a fragment of growth hormone that did not raise IGF-1 in trials.

Is AOD-9604 better than tesamorelin in fat-metabolism research?

The cited studies do not compare them directly. Tesamorelin has controlled evidence in people with HIV. The AOD-9604 human paper cited here reports safety, rather than weight-change findings, so it cannot establish a ranking.

Is AOD-9604 an approved weight-loss medicine?

No. AOD-9604 is handled here as a research material. Its listing on the FDA compounding safety-risk page does not make it an approved medicine.

Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Falutz et al., 2007, N Engl J Med, PMID 18057338; FDA safety-risk listing, content current April 22, 2026.

Order AOD-9604, 10mg research vial

Order AOD-9604. Ships as soon as stock arrives · After dispatch: 5 to 10 business days. Order support on WhatsApp.

Order Now

Batch certificate pending · Ships as soon as stock arrives · Order support on WhatsApp

Chat with us